Plain-English translation of NCT07694336 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research study is testing whether quinacrine, a medication originally used to treat malaria starting in the 1930s, can help treat cutaneous lupus erythematosus (CLE)โa condition where your immune system mistakenly attacks your skin, causing rashes and sores. While some doctors have used this medication for CLE based on their experience, it has not yet been formally approved by the FDA for this use. This trial will carefully study how safe and effective the medication is for treating your skin symptoms.
Although doctors have observed that this medication may help reduce skin inflammation in lupus patients, it has never been formally tested in a rigorous clinical trial. This study aims to gather solid scientific evidence about whether the treatment should become a standard option for people with CLE who haven't responded well to current treatments.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will be in this study for about 28 weeks (roughly 6โ7 months). For the first 12 weeks, you have a 50/50 chance of receiving either the actual medication or a placebo (a pill with no active drug); neither you nor the study team will know which one you're taking. During weeks 13โ28, all participants receive the actual medication. You will take one pill by mouth daily and attend study visits so the researchers can monitor your skin symptoms and check your health through blood tests and skin assessments.
AI-generated summary from trial data ยท Aug 29, 2026 ยท Not medical advice
United States